Level | OR (95% CI) | ||
Round 1 | Round 2 | Two doses | |
(A) All LGA model | |||
Unadjusted* | ─ | ─ | ─ |
Adjusted for age† | ─ | ─ | ─ |
Modified by age‡ | ─ | ─ | ─ |
1–4 Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 1.41 (1.06 to 1.88) | 1.08 (0.73 to 1.59) | 1.39 (1.06 to 1.83) |
≥15 Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 0.80 (0.64 to 0.98) | 0.95 (0.78 to 1.67) | 0.86 (0.70 to 1.06) |
(B) LGA-specific model | |||
Maiduguri | |||
Adjusted for age† | |||
Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 0.63 (0.43 to 0.94) | 0.67 (0.45 to 1.00) | 0.68 (0.47 to 1.00) |
Modified by age‡ | |||
≥15 Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 0.40 (0.22 to 0.71) | 0.62 (0.38 to 1.01) | 0.50 (0.29 to 0.93) |
Jere | |||
Modified by age‡ | |||
1–4 Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 1.95 (1.24 to 3.08) | 1.17 (0.69 to 1.98) | 2.04 (1.34 to 3.12) |
5–14 Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 0.58 (0.41 to 0.84) | 0.63 (0.34 to 1.17) | 0.58 (0.41 to 0.83) |
Mafa | |||
Unadjusted* | |||
Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 1.31 (1.07 to 1.59) | 1.27 (0.94 to 1.73) | 1.23 (1.00 to 1.51) |
Adjusted for age† | |||
Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 1.24 (1.02 to 1.51) | 1.16 (0.83 to 1.62) | 1.18 (0.95 to 1.46) |
Modified by age‡ | |||
5–14 Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 1.50 (0.95 to 2.36) | 1.64 (0.92 to 2.96) | 1.50 (1.04 to 2.16) |
Konduga | |||
Unadjusted* | |||
Female | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
Male | 0.94 (0.74 to 1.21) | 1.43 (1.04 to 1.95) | 0.99 (0.74 to 1.14) |
ORs and CIs were estimated using survey-weighted logistic regression. ORs in bold show statistically significant difference. The odds of an outcome is the ratio of the probability the outcome occurs to the probability the outcome does not occur. An OR compares the relative odds of an outcome between two groups. In our case, our outcome is vaccine coverage, so the ORs compare the odds of vaccine coverage between two groups. Specifically, we report ORs of vaccine coverage comparing males to females. We interpret these ORs as follows: OR=1 means no difference in the odds of vaccine coverage between males and females; OR >1 means males have a higher odds of vaccine coverage than females; OR <1 means males have a lower odds of vaccine coverage than females.
*Model was unadjusted for any covariates.
†Model was adjusted for age group.
‡Model included an interaction between age group and sex to allow age to modify the effect of sex on crude coverage.
(A), All LGA model; (B), LGA-specific model; crude coverage, card-verified plus self-reported coverage; LGA, Local Government Area; (ref), reference group.